Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
HIV fusion inhibitor |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2003
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J05AX07
|
| gptkbp:CASNumber |
159519-65-0
|
| gptkbp:developedBy |
gptkb:Roche
gptkb:Trimeris |
| gptkbp:genericName |
gptkb:enfuvirtide
|
| gptkbp:hasMolecularFormula |
C204H301N51O64
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fuzeon
|
| gptkbp:indication |
treatment-experienced HIV patients
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Genentech
|
| gptkbp:mechanismOfAction |
inhibits fusion of HIV-1 with CD4+ cells
|
| gptkbp:notEffectiveAgainst |
gptkb:HIV-2
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:proteinOrPeptide |
yes
|
| gptkbp:PubChem_CID |
16129668
DB00109 |
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
injection site reaction
hypersensitivity bacterial pneumonia |
| gptkbp:synonym |
gptkb:T-20
gptkb:enfuvirtide |
| gptkbp:UNII |
Q1K0A10Z02
|
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:Roche
|
| gptkbp:bfsLayer |
6
|